I am recommending we roll our SPDR S&P Biotech ETF (XBI) put out two weeks to generate a large chunk of cash. The hope is to close the position early with a nice profit. Note that the new put expires on a Thursday, as the market is closed on Friday, April 7, in observance of…
Below are the trades I recommended in today’s Options Income Blueprint Live Trading Session. Note that option prices may have moved since the Live Trading…
I don’t love the way SPDR S&P Biotech ETF (XBI) is trading. I am recommending we exit our put now with a small loss rather than risk having to roll the position out a week. Current Stock Price: $85.10 Cash in Hand: $0.75 Action: Buy to close the XBI Feb Monthly (2/17) 85 Put Current…
I am recommending we sell a put on SPDR S&P Biotech ETF (XBI) to take advantage of the risk-on trade. The sector has outperformed the broader market so far this year, though not by a crazy amount. Given that the biotech sector is more volatile than most, we can collect an attractive premium for selling…
I am recommending we close our SPDR S&P Biotech ETF (XBI) put early rather than hold through expiration and risk the position turning against us. Our active recovery strategy has allowed us to walk away from a position that was deep underwater – with a net debit as high as $14.77 at one point –…
Moderna (MRNA) has fallen more than 18% in the past two weeks since topping out above $212. This followed a sharp run-up in mid-December on news its personalized vaccine candidate reduces the risk of melanoma recurrence or death by 44% when given to patients in combination with Merck’s (MRK) Keytruda. Some of the selling can…
Moderna (MRNA) is holding onto the big gains it made after it was announced that its personalized vaccine candidate reduces the risk of melanoma recurrence or death by 44% when given to patients in combination with Merck’s (MRK) Keytruda. I am recommending we roll our put out two weeks to generate more income while lowering…
I am recommending we roll our Applied Materials (AMAT) and SPDR S&P Biotech ETF (XBI) puts out one week to generate more income and reduce our net debits on the positions. With AMAT, we are also rolling up to a higher strike to capture more income following the pop in shares this week. XBI has…
I am recommending we roll our Applied Materials (AMAT), Mosaic (MOS), Moderna (MRNA) and SPDR S&P Biotech ETF (XBI) puts to generate more income and reduce our net debits on the positions. AMAT Dec Week One (12/2) 100 Put Current Stock Price: $103.85 Net Debit: $8.08 Action: Buy to close the AMAT Dec Week One…
The chip sector continues to advance, and our Micron Technology (MU) call is deep in the money. I am recommending we roll it out to the December monthly expiration and up to a higher strike price to avoid being called out of shares. While we will need to spend some cash to do so, we…
